The trademark ORZELIA was filed by SPERO THERAPEUTICS, INC., a U.S. corporation (the "Applicant"). The application was published for oppositions on June 1, 2021, and received one opposition filed on September 1, 2021 by Bristol-Myers Squibb Company on Likelihood of confusion. the opponent was represented by Hogan Lovells (Alicante) S.L. & Cia. and proceedings were handled in English, and the oppositon was dismissed by the Euorpean Union Intellectual Property Office with decision issued September 1, 2021
The application was filed in English, and English was also language of all opposition proceedings (Italian was selected as the second language).